Moody Aldrich Partners LLC Has $3.72 Million Stake in BridgeBio Pharma, Inc. $BBIO

Moody Aldrich Partners LLC decreased its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 25.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 71,580 shares of the company’s stock after selling 23,855 shares during the quarter. Moody Aldrich Partners LLC’s holdings in BridgeBio Pharma were worth $3,718,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new position in shares of BridgeBio Pharma during the 2nd quarter valued at $3,856,000. Corient Private Wealth LLC bought a new stake in BridgeBio Pharma in the second quarter worth $643,000. Moss Adams Wealth Advisors LLC increased its position in BridgeBio Pharma by 49.2% during the second quarter. Moss Adams Wealth Advisors LLC now owns 24,172 shares of the company’s stock worth $1,044,000 after buying an additional 7,970 shares during the last quarter. Baird Financial Group Inc. bought a new position in BridgeBio Pharma during the first quarter valued at about $1,429,000. Finally, Bosun Asset Management LLC lifted its position in shares of BridgeBio Pharma by 119.7% in the second quarter. Bosun Asset Management LLC now owns 26,154 shares of the company’s stock worth $1,129,000 after buying an additional 14,250 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on BBIO shares. JPMorgan Chase & Co. increased their price objective on BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a report on Friday, November 7th. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of BridgeBio Pharma in a report on Monday, November 3rd. Cantor Fitzgerald lifted their price target on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. UBS Group upped their price objective on shares of BridgeBio Pharma from $72.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Finally, The Goldman Sachs Group raised their target price on shares of BridgeBio Pharma from $55.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Twenty-one equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.63.

Insider Transactions at BridgeBio Pharma

In other news, Director Andrew Lo sold 55,000 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $65.69, for a total transaction of $3,612,950.00. Following the sale, the director owned 50,583 shares of the company’s stock, valued at approximately $3,322,797.27. This trade represents a 52.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronald J. Daniels sold 61,031 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $63.72, for a total value of $3,888,895.32. Following the sale, the director owned 16,991 shares in the company, valued at approximately $1,082,666.52. This represents a 78.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 587,215 shares of company stock worth $38,801,501. 18.20% of the stock is currently owned by company insiders.

BridgeBio Pharma Price Performance

NASDAQ:BBIO opened at $76.49 on Thursday. BridgeBio Pharma, Inc. has a one year low of $27.32 and a one year high of $78.44. The company has a fifty day moving average price of $69.48 and a 200 day moving average price of $56.19. The stock has a market cap of $14.74 billion, a P/E ratio of -18.30 and a beta of 1.26.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The firm had revenue of $120.70 million for the quarter, compared to the consensus estimate of $107.71 million. During the same quarter last year, the firm posted ($0.86) EPS. The business’s revenue for the quarter was up 4318.0% on a year-over-year basis. As a group, equities research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.